Alvotech and stada add to strategic alliance through denosumab partnership

Reykjavik, iceland and bad vilbel, germany, june 11, 2024 (globe newswire) -- alvotech and stada are strengthening their existing strategic alliance for high-quality, cost-effective biosimilars by extending their partnership to cover avt03, a clinical-stage biosimilar candidate referencing the prolia®/xgeva® (denosumab) medicines for osteoporosis and cancer-related bone loss respectively.
ALVO Ratings Summary
ALVO Quant Ranking